We are live on ! Find out more

HIND

Vyome Holdings

HIND

Market cap $15.5M

2.21 USD

0.00

0%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

2.15

-0.06

2.71%

1 day

0%

5 days

0.91%

1 month

11.06%

3 months

-5.96%

6 months

-35.19%

Year to date

-37.75%

1 year

-76.98%

5 years

-100%

10 years

-100%

About: Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Employees: 18

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update. Krishna Gupta, Chairman, Vyome Holdings, said, “Vyome continues to execute with focus and discipline across its development programs while maintaining a methodical and conservative approach to capital alloc.

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #VT1953--Vyome Holdings, Inc. (NASDAQ: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, announces that the China National Intellectual Property Administration (CNIPA) has granted a patent (Chinese Patent No. ZL 2021 1 0758695.X) covering formulation and therapeutic use claims relating to its proprietary besifloxacin topical gel program for infl.

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said, “Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical need focused on.

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (“Impetis”), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Janus kinase (JAK) inhibitors are immunomodulatory drugs that treat autoimmune and inflammatory conditions by blocking JAK enzymes. Several JAK inhibitors are FDA-approved to treat a wid.

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026.

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds (“MFW”) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome,.

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program. Key anticipated benefits of an orphan drug designation include 7 years of U.S. market exclusivity, up to 25% of tax credits on clinical trials conducted in the USA, exemption from FDA Prescrip.

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

See News Rankings

Price charts implemented using Lightweight Charts™